MiR-132

Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study

Retrieved on: 
Thursday, September 8, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Clinical Trials, Patient, LVEF, Degenerative disease, RNA transfection, RNA, Safety, Gene, Medication, Heart, Echocardiography, Heart failure, Blood, Myocardial infarction, Quality of life, CSO, PCR, Fibrosis, European Heart Journal, Standard of care, Therapy, SOC, Founder, MiR-132, HF, CE, ECHO, Trial of the century, Medical device, EU

By using the CardiorHealth miR-132 PCR kit, Cardior ensures consistent measurement of miR-132 levels following CDR132L treatment across all clinical trial centers as an indicator of the target engagement and the compounds mechanism of action.

Key Points: 
  • By using the CardiorHealth miR-132 PCR kit, Cardior ensures consistent measurement of miR-132 levels following CDR132L treatment across all clinical trial centers as an indicator of the target engagement and the compounds mechanism of action.
  • Cardior is developing CDR132L as a therapeutic candidate to improve cardiac systolic and diastolic function in patients with heart failure.
  • The CardiorHealth miR-132 PCR kit is the first PCR kit designed to monitor the treatment with a non-coding RNA-based therapeutic.
  • CE mark approval of the kit was based on the clinical evaluation of the test in patients receiving various doses of CDR132L or placebo, where the kit demonstrated comparable results to a similar testing protocol used in Cardiors Phase 1b clinical study.

Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA-Based Lead Candidate CDR132L in Heart Failure Patients Post-Myocardial Infarction

Retrieved on: 
Wednesday, July 20, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Patient, Medication, Echocardiography, Myocardial infarction, Food, Trial of the century, European Heart Journal, CEO, RNA, MI, Biomarker, LVEF, CSO, Risk, Fibrosis, MiR-132, HF, Safety, Degenerative disease, ECHO, Gene, Quality of life, Chairperson, Heart failure, RNA transfection, FDA, MD, Heart, Cardiology, Therapy, Survival, Entrepreneurship, SOC, MicroRNA, Founder, Prevalence, Standard of care, Pharmaceutical industry, Medical imaging, Medical device

Cardiac remodeling is a debilitating and often life-threatening consequence of myocardial infarction that contributes to the development of heart failure.

Key Points: 
  • Cardiac remodeling is a debilitating and often life-threatening consequence of myocardial infarction that contributes to the development of heart failure.
  • Even if resolved, MI can lead to permanent damage of the heart cells initiating pathological cardiac remodeling resulting in the development of heart failure.
  • Heart failure remains one of the leading causes of death globally with only limited intervention options.
  • Levels of miR-132 are elevated in the cardiac tissue of heart failure patients, triggering well-defined molecular pathways.

Secondcell Bio Publishes Biotechnology for Improved Drug Discovery Originating from The Rockefeller University

Retrieved on: 
Wednesday, September 15, 2021
Library, Rockefeller University, Garbage, United States Air Force Scientific Advisory Board, Gene, Scientist, MiR-132, NOAAS Oregon II (R 332), Nobel Prize, United Airlines Flight 232, Time, Research, Springer Nature, Biology, Plasmid, Pressure, Gene expression, GABAA, CHO, Epithelium, Kaay Raav Tumhi, CFTR, Biotechnology Letters, RNA transfection, Sickle cell disease, Chromosome, CRISPR, Investment, Cell, Biotechnology, Drug discovery, FDA, Genetic engineering, Neuron, A-DNA, G protein-coupled receptor, Subtypes of HIV, Technology, DNA, MCS, Abstract, Membrane protein, HEK, Chromolithography, RNA, Zinc finger protein 532, Goal, Method, Cell engineering, Efficiency, Phajo Drugom Zhigpo, LLC, Epistasis, GPCR, Multiple, Industry, Partnership, Disease, Flow cytometry, Scale, Forestry, Pharmaceutical industry, Vaccine, Fine chemical, Antibiotics

"Little more than a random and highly inefficient enterprise, drug discovery today is "garbage in, garbage out" enterprise.

Key Points: 
  • "Little more than a random and highly inefficient enterprise, drug discovery today is "garbage in, garbage out" enterprise.
  • Currently, the industry average failure rate for drug discovery programs in pharmaceutical companies is reported to be approximately 98%.
  • This work was performed by Chromocell Corporation, a biotechnology company spun out of The Rockefeller University based upon the technology.
  • Secondcell, Secondcell Bio, Cellbrary, Cellbraries, Chromo-Plasmid, pChromo-Plasmid, Chromo-Tag, Drugomics, Drug Discovery at Scale, and the Secondcell Bio logo are trademarks of Secondcell Bio, LLC.